The bioequivalence of two commerical blackcurrant extracts and the effect of caffeine on the appearance of blackcurrant polyphenolics in blood plasma in healthy participants.
- Conditions
- utrient absorptionNutrient absorptionOther - Research that is not of generic health relevance and not applicable to specific health categories listed above
- Registration Number
- ACTRN12620001248954
- Lead Sponsor
- Dr. Dominic Lomiwes
- Brief Summary
The aim of this work was to evaluate the anthocyanin bioequivalence of a spray-dried blackcurrant powder with a commercially available anthocyanin-enriched blackcurrant extract and to determine the effect of caffeine on the bioavailability of spray-dried blackcurrant anthocyanins. Co-consuming caffeine with the spray-dried blackcurant powder did not significantly affect total or monomeric anthocyanin bioavailability up to 6 hours post consumption, as indicated by similar Tmax, Cmax and AUC, compared with consuming spray-dried blackcurant powder powder alone. Comparison of intervention bioavailability profiles showed a slower absorption of anthocyanins in the anthocyanin-enriched extract group as indicated by the Tmax after treatment intake. Despite this delay, no significant differences in Cmax and AUC were observed between the three blackcurrant interventions, indicating that the extent of anthocyanin bioavailability between three treatment groups is similar. The delayed Tmax observed in the encapsulated anthocyanin-enriched extract intervention may be attributed to the time taken for the gelatine capsule to disintegrate and release the blackcurrant powder in the stomach.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 9
Healthy individuals (male or female) 18 – 55 years who are able to provide written consent to participate in this study will be selected from this study.
Participants will be excluded if they are unwilling or unable to provide written consent or comply with the study procedures. Participants will also be excluded if they have known hypersensitivity or intolerance to caffeine, blackcurrants or berryfruit-derived products. In addition, participants will be excluded if they are pregnant, planning to get pregnant in the immediate future or have any of the following conditions: (i) blood borne diseases (e.g. hepatitis), (ii) clinically diagnosed high/low blood pressure, (iii) recent bacterial or viral illness or (iv) are taking medication that affects the properties of blood (e.g. blood clotting).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma anthocyanin concentrations will be measured in blood samples collected from all participants at the same timepoints on all trial days.[ This will be measured from blood samples collected at 0, 1, 2, 4 and 6 hours after treatment consumption during each trial day using validated in-house high performance liquid chromatography (HPLC) methods.]
- Secondary Outcome Measures
Name Time Method Blood glucose levels[ On each trial day, blood glucose levels will be measured from an aliquot of venous blood samples collected at 0, 1, 2, 4 and 6 hours after treatment consumption. Glucose will be measured using point-of-test biosensors.]